12 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 4.2% per year over the past 5 years.
Operating margin has contracted, at -398.8% in the latest year.
Financial health
Total debt has grown faster than revenue (44.9% vs 4.2% per year).
Operating income covered interest expense -685.2× in the latest year, down from -9.5× 5 years ago.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$12M
-$54000
99.2%
-398.8%
—
—
$968000
2024
$12M
-$39250
0.0%
-263.8%
-$29M
—
$8M
2023
$10M
-$41900
0.0%
-351.3%
—
—
$6M
2022
$12M
-$48400
0.0%
-287.8%
-$33M
—
$5M
2021
$4M
-$52600
0.0%
-939.1%
-$35M
—
$17M
2020
$9M
-$34M
0.0%
-283.9%
-$15M
—
$8M
2019
$6M
-$39M
0.0%
-501.3%
—
—
$3M
2018
$4M
-$32M
0.0%
-698.0%
-$23M
—
$3M
2017
$4M
-$22M
0.0%
-785.3%
—
$13M
$520698
2016
$141523
-$15M
0.0%
-9599.8%
-$15M
$4M
$950979
2015
$258381
-$16M
0.0%
-4816.7%
—
$6M
$8M
2014
$0
-$9M
—
—
—
—
$845192
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$20M
$9M
94.3%
50.2%
—
—
$7M
Dec '25
$3M
-$23M
32.0%
-656.6%
—
—
$968000
Sep '25
$3M
-$10M
82.7%
-234.8%
—
—
$4M
Jun '25
$3M
-$11M
82.3%
-268.8%
—
—
$2M
Mar '25
$2M
-$11M
76.7%
-425.5%
—
—
$6M
Dec '24
$4M
-$10M
84.1%
-232.5%
-$8M
—
$8M
Sep '24
$3M
-$10M
82.6%
-233.7%
-$6M
—
$13M
Jun '24
$3M
-$10M
84.3%
-264.5%
—
—
$16M
Mar '24
$2M
-$9M
81.7%
-349.4%
—
—
$12M
Dec '23
$2M
-$9M
70.1%
-328.6%
—
—
$6M
Sep '23
$3M
-$8M
81.7%
-312.4%
-$7M
—
$3M
Jun '23
—
-$12M
—
—
-$9M
—
$9M
Mar '23
—
-$12M
—
—
-$10M
—
$14M
Dec '22
—
-$8M
—
—
-$6M
—
$5M
Sep '22
—
-$13M
—
—
-$9M
—
$11M
Jun '22
—
-$9M
—
—
—
—
$9M
Mar '22
—
-$18M
—
—
—
—
$17M
Dec '21
—
-$14M
—
—
-$9M
—
$17M
Sep '21
—
-$12M
—
—
-$9M
—
$12M
Jun '21
—
-$14M
—
—
—
—
$22M
Valuation over time
How the market has priced JAGX against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has risen from 0.0× (Mar '23) to 0.1× (Jun '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is JAGX growing its revenue and profit?
Over the past 5 years, Jaguar Health, Inc.'s revenue has grown 4.2% per year. These are computed facts, not advice.
How much debt does JAGX have?
As of FY2025, Jaguar Health, Inc. reported — of total debt against $968000 of cash; operating income covered interest expense -685.2×.
What is JAGX's profit margin?
In FY2025, gross margin was 99.2%, operating margin -398.8%, and net margin -0.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.